Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Multispecific Approach Could Improve I-O Side Effect Profile, Says Numab

Executive Summary

Multispecific antibody therapeutic developer Numab – run by two former Esbatech executives – has come of age with a deal in the IO space that validates its technology. Could this mean bispecific programs have had their day?

You may also be interested in...



Deal Watch: Novartis Signs Deals In Migraine & Diabetes

Novartis will invest in the Calgary-based Parvus and collaborate on a Navacim candidate for type 1 diabetes. Japan's Sawai moves into the US market by acquiring Upsher-Smith's generics business, while Denovo acquires a suspended depression candidate from AMRI for its personalized development approach.

Avillion Has Faith In Merck's Ablynx-Rejected Psoriasis Drug

Avillion – which seeks co-development deals for products that otherwise could languish in busy big pharma pipelines – is taking on development of Merck's early-stage psoriasis drug, M1095, despite originator Ablynx having opted out of a co-development arrangement with the German firm for the drug four years earlier.

UK Reimbursement Decisions Focus Mostly On Cancer

The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.

Topics

Related Companies

UsernamePublicRestriction

Register

SC027449

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel